is the amyloid-beta (Aβ) plaque, which could not be detected during life until recently. Advances have permitted its detection in cerebrospinal fluid and with positron emission tomography (PET ...

This finding suggests that a single positron emission tomography (PET) scan assessing amyloid beta protein levels in the brain could be sufficient to predict the rate of cognitive decline in ...

The current gold standards — PET scans of brain amyloid and analysis ... For AD, most people think of amyloid-Beta, but there is another protein called p-Tau (phosphorylated tau).

The revised criteria offer guidance for clinicians to determine when amyloid and tau PET are recommended. Criteria were divided into 17 common clinical scenarios with three subcategories of ...

Eisai has tackled AD drug discovery for four decades, resulting in a symptomatic breakthrough treatment in the 1980s and the continued development of anti-amyloid and anti-tau antibodies today.

Alzheimer’s disease (AD) is the most common form of dementia in the elderly. Although the prevalence of AD increases with age, studies have indicated that a number of elderly patients have AD ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer’s disease in older adults. The diagnostic criteria for limbic-predominant ...

advanced coverage for beta-amyloid PET imaging by removing coverage with evidence development (CED), allowing Medicare to cover amyloid PET scans outside of a research protocol. Change begins with ...